Citi upgrades Haemonetics to Buy, raises target to $123
Citi upgraded Haemonetics (NYSE:HAE) to Buy and lifted its target to $123, citing EPS upside if HAE recaptures CSL Plasma revenue and referencing its Jan 9, 2026 acquisition of Vivasure Medical to add vascular closure technology.